Hypertension in cyclosporin A-treated patients is independent of circulating endothelin levels
Article first published online: 4 AUG 2009
1995 Blackwell Publishing Ltd
Journal of Internal Medicine
Volume 238, Issue 1, pages 71–75, July 1995
How to Cite
FORSLUND, T., HANNONEN, P., REITAMO, S. and FYHRQUIST, F. (1995), Hypertension in cyclosporin A-treated patients is independent of circulating endothelin levels. Journal of Internal Medicine, 238: 71–75. doi: 10.1111/j.1365-2796.1995.tb00901.x
- Issue published online: 4 AUG 2009
- Article first published online: 4 AUG 2009
- Received 5 November 1994, accepted 26 January 1995
- atrial natriuretic peptide;
- cyclosporin A;
- palmoplantar pustulosis;
- rheumatoid arthritis
Abstract. Objectives. To measure blood pressure (BP), plasma endothelin-1 (ET-1), atrial natriuretic peptide (ANP), antidiuretic hormone (ADH) and aldosterone (ALDO) concentration, and plasma renin activity (PRA) in patients treated with a low-dose cyclosporin A (CyA).
Design. An open study of patients with rheumatoid arthritis (RA) or palmoplantar pustulosis (PPP).
Setting. Out-patient clinics at the Central Hospital of Jyväskylä and Helsinki University Central Hospital.
Subjects. CyA was given to 25 patients with RA and to 10 patients with PPP.
Intervention. RA patients were given CyA at a dose of 2.5±0.13 mg kg−1 body weight (BW) to 3.47±0.79 mg kg−1 BW (mean values±SD) at the start of the study and after 6 months, respectively, and the CyA dose was 2.67±0.13 mg kg−1 BW decreasing to 2.07±0.96 mg kg−1 (P < 0.001) after 4 months in PPP subjects.
Results. Systolic (sBP) and diastolic blood pressure (dBP) increased from 127.8±13.6/79.7±8.4 mmHg to 140.0±19.8/83.8±9.7 mmHg during the study (P < 0.03). Plasma ET-1, ANP, ALDO and ADH concentration and PRA did not change during 4 to 6 months of CyA treatment. The plasma ANP concentration was constantly higher in CyA-treated RA patients (112±87 ng l−1) to 118±78 ng l−1) than in PPP patients (37.3±26 ng l−1 to 47.7±39.9 ng l−1; P < 0.02). The serum creatinine concentration remained within the normal range, but increased from baseline (76.7±11.9 μmol l−1), to 90±15.4 μmol l−1 (P < 0.001). The serum magnesium concentration decreased significantly (P < 0.005) after 6 months of CyA treatment in RA patients. No correlation was found between serum creatinine and plasma ET-1 concentration.
Conclusions. Increased blood pressure during CyA treatment was independent of circulating ET-1 levels. A low dose of CyA did not induce increased ET-1 synthesis as judged from plasma samples. The high plasma ANP level observed in RA patients could be due to fluid retention caused by concomitant treatment with non-steroid anti-inflammatory drugs. Fluid retention and decreased magnesium levels could also be involved in the development of hypertension in CyA-treated subjects.